Recent studies have shown that the CXCR4 antagonist AMD3100, also known as plerixafor (Marketed Mozobil® (Sanofi, Paris, France)), effectively blocks the CXCL12/CXCR4 interaction, thereby inhibiting the migration of Tregs and other immune cells within the tumor microenvironment [20]. This evidence concerns the gene CXCL12 and neoplasm.